BioPharma Resources

Drug Trial Radar · NCT07897305

Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

Efficacy of Mazdutide in Reducing Recurrence After Catheter Ablation in Obese Patients With Atrial Fibrillation: A Multicenter, Superiority, Open-label, Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Oct 25, 2026

Primary completion

Dec 30, 2028

Study completion Dec 30, 2028

Sponsor

Lead sponsor
Beijing Anzhen HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, superiority randomized controlled trial enrolling adult patients aged 18 to 75 years. All participants have abdominal obesity (BMI ≥ 28 kg/m² with specific waist circumference standards) and non-valvular atrial fibrillation, and have successfully regained normal heart rhythm after their first catheter ablation. The study aims to compare the efficacy and safety of weekly mazdutide injection with conventional routine care in preventing heart rhythm recurrence within 12 months after ablation (excluding a 3-month early recovery blanking period). A total of 24 months will be spent recruiting participants, followed by a 12-month follow-up period. Participants are randomly divided into two groups. The intervention group receives escalating-dose mazdutide subcutaneous injections starting within 48 hours after ablation alongside standard health guidance on diet, exercise and lifestyle. The control group only receives the same routine health guidance without mazdutide treatment. The primary efficacy endpoint is recurrence of atrial arrhythmias (including AF, atrial flutter, and atrial tachycardia) recorded on a standard 12-lead surface ECG for ≥10 seconds, or on a 24-hour Holter monitor (including single-lead ECG patches) for \>30 seconds, at 12 months after a single ablation procedure (after a 3-month blanking period), without the use of any Class I/III antiarrhythmic drugs (AADs).

Conditions

  • Atrial Fibrillation (AF)
  • Ablation Treatment
  • Obesity & Overweight
  • Mazdutide

Interventions

  • MazdutideDrug

    1. Initiation of mazdutide subcutaneous injection within 48 hours after catheter ablation. Starting dose: 2 mg subcutaneously once weekly using a single-dose pen auto-injector. The initial dose is 2 mg once weekly, increased by 2 mg every 4 weeks during dose escalation, with a maximum dose of 6 mg. The target dose is individualized based on the patient's weight-loss effect. Once the patient achieves a 10% reduction in body weight, the dose is maintained for continued treatment. 2. Patients receive health guidance before discharge, including diet, exercise, smoking cessation, and alcohol abstinence.

  • Conventional treatmentOther

    Patients receive health guidance before discharge, including diet, exercise, smoking cessation, and alcohol abstinence.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence of atrial arrhythmias at 12 months after a single ablation procedure without the use of any Class I/III antiarrhythmic drugs (AADs).Time frame: From enrollment to the end of treatment at 52 weeks
  2. Composite serious adverse events (SAEs) occurring during the perioperative period and follow-up period.Time frame: From enrollment to the end of treatment at 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China.

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.